# Ascendis Pharma Q3 Profitability Shift

> Ascendis Pharma's TransCon platform now generates €370m revenue with 72.9% YoY growth.
- Title: Ascendis Pharma Q3 Profitability Shift | Shortify
- Summary: Ascendis Pharma's TransCon platform now generates €370m revenue with 72.9% YoY growth.
- Keywords: ascendis pharma, transcon platform, q3 2026, revenue growth, pharmaceuticals, biotechnology, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/ascendis-pharma-asnd-transcon-platform-profitability-inflection-signals-the-transition-to-commercial-scale-earnings
- Author: Newsdesk
- Published: 2026-11-12T19:55:58+00:00
- Read time: 1 min
- Topics: ascendis pharma, transcon platform, q3 2026, revenue growth, pharmaceuticals, biotechnology
## Q3 2026 Results
Ascendis Pharma reported Q3 2026 revenue of €370 million, a 72.9% year-over-year increase from €214 million in Q3 2025.
## Commercial Product Revenue Surge
Commercial product revenue surged 88.8% to €365.7 million, driven by YORVIPATH® generating €291 million.
## Operating Profitability
Non-IFRS operating profit reached €156 million, a 271% year-over-year increase from €42 million.
## Cash Flow and Share Repurchase
Operating cash flow totaled €463 million, with 1,998,999 shares repurchased for $459 million.
## Investor Catalysts
Three key catalysts will define ASND investment case through 2027: EU filing decision, BioMarin dispute settlement, and YORVIPATH enrollment trajectory.
## Key takeaway

Ascendis Pharma achieved €370 million in Q3 2026 revenue, marking a transition from development-stage to cash-generating operations.